Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Sep 8, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring a new technology called breathprinting, or electronic nose (E-Nose), to see how well it can measure how patients with malignant pleural mesothelioma (MPM) respond to standard treatments. Researchers want to track changes in the breathprints of participants over time and compare these changes to results from traditional imaging scans and blood tests that look for signs of MPM. The goal is to find out if the E-Nose can provide useful information about a patient's response to treatment.

To participate in the study, individuals must be between 30 and 85 years old and have recently been diagnosed with MPM. They should not have a history of other types of cancer that could affect the lungs or chest area. Participants will need to give their consent to join the study and may undergo some procedures related to the trial. If you or a loved one meets these criteria, this study could offer an opportunity to be part of important research while receiving standard treatment for MPM.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 30-85 years
• • No history of thoracic cancer or extrathoracic cancer potentially involving pleural metastases (i.e., breast, gastric, colon, or pancreas cancer)
• • Recent diagnosis of MPM
• • Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study, and signed standard surgical consent for surgical resection
• Exclusion Criteria:
• • Aged \<30 or \>85 years at the first outpatient visit
• • History of thoracic or extrathoracic cancer that puts the subject at risk for pleural or pulmonary metastases